Search

Limited epidemiological data exist describing how patients engage with various treatments for overactive bladder (OAB). To improve care for patients with OAB, it is essential to gain a better understanding of how patients interface with OAB treatments longitudinally, that is, how often patients change treatments and the pattern of this treatment change in terms of escalation and de-escalation.To describe treatment patterns for women with bothersome urinary urgency (UU) and/or urgency urinary incontinence (UUI) presenting to specialty care over 1 year.The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) study enrolled adult women with bothersome UU and/or UUI seeking care for lower urinary tract symptoms (LUTS) between January 2015 and September 2016. An ordinal logistic regression model was fitted to describe the probabilities of escalating or de-escalating level of treatment during 1-year follow-up.Among 349 women, 281 reported UUI and 68 reported UU at baseline. At the end of 1 year of treatment by a urologist or urogynecologist, the highest level of treatment received by participants was 5% expectant management, 36% behavioral treatments (BT), 26% physical therapy (PT), 26% OAB medications, 1% percutaneous tibial nerve stimulation, 3% intradetrusor onabotulinum toxin A injection, and 3% sacral neuromodulation. Participants using BT or PT at baseline were more likely to be de-escalated to no treatment than participants on OAB medications at baseline, who tended to stay on medications. Predictors of the highest level of treatment included starting level of treatment, hypertension, UUI severity, stress urinary incontinence, and anticholinergic burden score.Treatment patterns for UU and UUI are diverse. Even for patients with significant bother from OAB presenting to specialty clinics, further treatment often only involves conservative or medical therapies. This study highlights the need for improved treatment algorithms to escalate patients with persistent symptoms, or to adjust care in those who have been unsuccessfully treated.

To compare 30-day postoperative complications following abdominoplasty with and without concomitant hysterectomy. Our secondary objective was to compare outcomes following abdominoplasty by route of hysterectomy.This was a retrospective cohort study using American College of Surgeons National Surgical Quality Improvement Program (NSQIP) Database from 2014 to 2018. We included women who underwent abdominoplasty alone (ABP) and abdominoplasty with concomitant hysterectomy (ABP+Hyst). The ABP+Hyst group included both abdominal hysterectomy (ABP+AH) and minimally invasive hysterectomy (ABP+MIH).Analysis included 9064 women of whom 2.4% had ABP+Hyst (216 ABP+AH and 53 ABP+MIH). Both ABP and ABP+Hyst had similar 30-day postoperative complication rates (11.5% vs. 14.1%, p=.22). Patients with ABP+Hyst had a longer length of hospital stay when compared to ABP alone [2 days (IQR 1-2) vs. 1 day (IQR 0-2), plt;.001). Operating time was longer in ABP+Hyst by 76 minutes (plt;.001). In a multivariable logistic regression model controlling for age, race, BMI, ASA class, smoking status, hysterectomy, operative time, and major medical comorbidity, concomitant hysterectomy was not associated with increased odds of 30-day postoperative complications. Both ABP+AH and ABP+MIH had low 30-day complication rates (15.3% vs. 9.4%, p=.273). However, ABP+MIH had a 38 minute longer median operating time (p=.008) but with a shorter length of stay by 1 day (plt;.001).Concomitant hysterectomy at the time of abdominoplasty was not associated with an increase in complications during the first 30-days after surgery regardless of route of hysterectomy. These data suggest that selected patients can safely be offered combined surgery.This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .